Alkermes Plc Q4 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Congratulations on the progress, and thank you for all the color. So maybe just 2 from me. First, in terms of LYBALVI gross to net, where do you think that will stabilize at? Is it sort of closer to that 2022 guidance or maybe closer to the VIVITROL and ARISTADA number? How do you think about balancing access versus script growth in 2022 and beyond? And then maybe I'll ask the second one as it probably goes a little bit in line with that. Thank you for the updated longer-term profitability targets, but I'm going to continue to dig a little. Did you consider putting up revenue targets publicly? Do you think that's something you could put out in the future just to sort of shore up that you do have growth in the business? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 16, 2022 / 1:00PM, ALKS.OQ - Q4 2021 Alkermes Plc Earnings Call

Question: Tiffany Sun - JPMorgan Chase & Co, Research Division - Analyst : This is Tiffany on for Cory. Congrats on the quarter. I just wanted to ask on how much of an impediment COVID has been with LYBALVI's first quarter on the market? Obviously, it looks pretty solid overall, but just wondering kind of COVID headwinds, and how they play into that? And then also, how much you're able to leverage your presence with ARISTADA to overcome some of these obstacles?